Hyperbaric Oxygen Therapy News: Latest Research & Developments (2026)

Last updated: May 2026. This page is updated monthly with the latest hyperbaric oxygen therapy research, clinical trials, and regulatory news. For a deeper dive, check out our comprehensive overview of HBOT research.

Hyperbaric oxygen therapy (HBOT) is one of the most actively researched treatments in regenerative medicine, with dozens of clinical trials underway across neurology, wound care, post-viral syndromes, and aging. The evidence base is growing fast, but it is also uneven: some indications have strong support from randomized controlled trials, while others remain in early or exploratory stages. Below is a comprehensive, reverse-chronological roundup of the most important HBOT studies, regulatory updates, and emerging research areas as of mid-2026.

2024-2025: Long COVID Trials Deliver Mixed Verdicts

Long COVID became one of the most closely watched applications of HBOT during the pandemic era. Two major randomized controlled trials published their results in 2024-2025, and they reached strikingly different conclusions. Our PubMed database covers this in detail.

HOT-LoCO: The Negative Trial (Sweden, 2025)

The HOT-LoCO trial (Hyperbaric Oxygen for Treatment of Long COVID-19 Syndrome) was a randomized, placebo-controlled, double-blind, phase II trial conducted at Karolinska University Hospital in Stockholm. Published in BMJ Open in April 2025, the study enrolled 80 patients (65 women, 15 men) and randomized them to receive either ten sessions of HBOT or a sham treatment.

The results were clearly negative. At 13 weeks, both groups showed improvement, but there was no statistically significant difference between HBOT and placebo on any primary or secondary endpoint. The physical functioning score showed a least-square mean difference of just 0.63 (95% CI: -7.04 to 8.29, p=0.87), and the role-physical score difference was 2.35 (95% CI: -5.95 to 10.66, p=0.57). The authors concluded that their data “do not provide any evidence of benefit for hyperbaric oxygen therapy in the treatment of Long Covid.”

This trial is important because it used a rigorous sham control and blinding protocol. The improvement seen in both the treatment and placebo groups highlights how important proper controls are in HBOT research.

The HOT-LoCO trial used just 10 sessions. The Israeli positive trial used 40. Dose matters enormously in HBOT research. Comparing these two trials as if they tested the same intervention is scientifically incorrect.

BaricBoost editorial note

The Israeli Positive Trial (Tel Aviv, 2022-2024)

On the other side of the ledger, a randomized controlled trial from the Sagol Center for Hyperbaric Medicine at Shamir Medical Center (led by Prof. Shai Efrati and Dr. Amir Hadanny) found significant benefits. Published in Scientific Reports in July 2022, the trial enrolled 73 patients with persistent post-COVID cognitive symptoms lasting more than three months. Thirty-seven patients received HBOT and 36 received sham treatment.¹

After 40 sessions at 2.0 ATA, HBOT participants showed significant improvements in cognitive function, fatigue, sleep quality, pain, and psychiatric symptoms. Brain MRI confirmed increased perfusion and white matter microstructure improvements. These differences were statistically significant across multiple validated outcome measures.

The debate between these two trials centers primarily on dose. Ten sessions versus 40 sessions represent substantially different treatment courses. The field is converging on the view that the number of sessions is a critical determinant of outcome, and that under-dosing may explain negative results in some trials.

Read more: HBOT for Lingering COVID-19 Symptoms

2020: The Aging Study That Made Headlines

In November 2020, researchers at Tel Aviv University published a study in Aging that generated worldwide media coverage. The trial exposed 35 healthy adults aged 64 and older to 60 hyperbaric sessions over 90 days at 2.0 ATA with 100% oxygen and intermittent air breaks.

Telomere length in immune cells increased by more than 20% across all measured cell types, with B cells showing increases up to 38% (p=0.0001).² Senescent T helper cells decreased by 37.3% (p<0.0001). These are recognized hallmarks of biological aging, and no other intervention had previously demonstrated this magnitude of telomere lengthening in humans.

Telomere length increased by more than 20% and senescent cell counts dropped by up to 37% after 60 HBOT sessions in healthy adults over 64. These are recognized biomarkers of cellular aging, and the changes exceeded anything previously documented from a single intervention.

Hachmo et al., 2020, Aging

Important caveats apply. The study had no placebo control, a small sample, and measured blood cell markers rather than clinical outcomes. Larger, controlled trials with clinical endpoints are needed. Still, the study opened a new line of inquiry and remains one of the most cited papers in the field.

Read more: Hyperbaric Chamber for Anti-Aging

Traumatic Brain Injury and Concussion

TBI research is one of the most active and contested areas in HBOT science. A 2025 meta-analysis pooling data from multiple trials (n=250 total participants) found significant improvements across all cognitive domains: memory (MD=10.13, p<0.00001), attention (MD=7.99, p<0.00001), general cognition (MD=7.47, p=0.003), and executive function (MD=7.16, p=0.002).³

Boussi-Gross et al. (2013): Post-Concussion Syndrome

A landmark 2013 trial published in PLOS ONE enrolled 56 patients with mild traumatic brain injury and persistent post-concussion syndrome 1-5 years after injury. Using a randomized crossover design, 40 HBOT sessions at 1.5 ATA produced significant improvements in cognitive function and quality of life. SPECT imaging confirmed that improvements correlated with increased metabolic activity in previously dormant but structurally intact brain tissue.⁴

VA and Military Studies: Mixed Results

The US Department of Defense funded two major trials in service members with blast-related mTBI. Neither found statistically significant differences in composite symptom scores between HBOT and sham. However, the sham procedure (pressurized air at 1.2 ATA) may itself have therapeutic effects, complicating the interpretation. Research continues with a new VA clinical trial actively recruiting.

Read more: Hyperbaric Chamber for Brain Injury

Wound Healing: The Strongest Evidence Base

Diabetic foot ulcers and chronic non-healing wounds remain the best-supported application of HBOT. A 2024 meta-analysis found HBOT significantly superior to standard care for wound healing at 8+ weeks (RR=2.39; 95% CI: 1.87-3.05; p<0.00001) and significantly reduced major amputation rates (RR=0.31; 95% CI: 0.18-0.52).⁵ A network meta-analysis ranked HBOT highest among all advanced wound therapies for both healing rate (SUCRA=0.814) and wound area reduction (SUCRA=0.730).

Read more: Hyperbaric Chamber for Wound Healing

Cancer: Adjunct to Radiation, Not a Cancer Treatment

HBOT is not a cancer treatment. The FDA has specifically warned against clinics promoting HBOT for cancer, and the UHMS does not list cancer among its approved indications. What HBOT is approved for in oncology is treating the side effects of radiation therapy. Late radiation tissue injury is one of the 14 FDA-cleared indications.

A 2026 review in CA: A Cancer Journal for Clinicians summarized evidence supporting HBOT for radiation-induced injury to the head and neck, bone, prostate, and bladder. The HONEY trial (JAMA Oncology) found significant improvement in pain and fibrosis in breast cancer survivors with late radiation side effects. Safety evaluations published in Medicina in 2025 found no evidence that HBOT promotes tumor growth or metastasis in patients with solid tumors.

Read more: Hyperbaric Chamber and Cancer

Neuroplasticity and Stroke Recovery

A 2013 RCT published in PLOS ONE by the Efrati group enrolled 74 chronic stroke patients (6-36 months post-stroke). Forty HBOT sessions at 2.0 ATA produced significant neurological improvements and quality-of-life gains. SPECT imaging revealed improvements correlated with elevated metabolic activity in brain regions where live tissue had been dormant, suggesting reactivation of functionally impaired but structurally intact neural tissue. Stroke is not currently an FDA-cleared indication.

Fibromyalgia

A 2015 crossover trial enrolled 60 women with fibromyalgia for at least two years. After two months of HBOT, 70% showed significant changes in brain activity on SPECT imaging and many reduced or eliminated pain medications. A 2023 follow-up RCT compared HBOT to pharmacological treatment in fibromyalgia patients with a TBI history and found HBOT superior on multiple outcome measures. Fibromyalgia is not an FDA-cleared indication.

FDA Regulatory Status

As of 2026, the FDA clears HBOT for approximately 14 medical conditions. The UHMS maintains the authoritative list:

Emergent: arterial gas embolism, acute carbon monoxide poisoning, central retinal artery occlusion, decompression illness, severe anemia when transfusion is not possible, impending compartment syndrome.

Urgent: acute peripheral arterial insufficiency, crush injuries, compromised skin grafts and flaps, gas gangrene, idiopathic sudden sensorineural hearing loss, intracranial abscess, necrotizing soft tissue infections.

Scheduled: acute thermal burns, chronic refractory osteomyelitis, diabetic foot ulcers (Wagner grade 3+), delayed radiation injury.

Off-label uses including long COVID, TBI, aging, and fibromyalgia are typically not covered by insurance. The FDA has issued warnings about clinics promoting HBOT for unapproved uses including cancer, Lyme disease, and Alzheimer’s disease.

Emerging Research Areas

Several applications are in early-stage research. None have strong evidence yet.

Fertility: A 2023 study in Reproductive Biology and Endocrinology found HBOT increased endometrial thickness from 5.76mm to 6.57mm (p=0.002) in women with resistant thin endometrium. Separate research has shown reduced sperm DNA fragmentation. Early findings only.

PTSD: A 2025 study in Brain and Behavior found a possible dose-response threshold effect in veterans with treatment-resistant PTSD. PTSD is not an approved indication.

Autism: A 2016 Cochrane-style review and a 2025 meta-analysis both found inconclusive evidence. The UHMS does not include ASD among approved indications.

The Bottom Line

HBOT research is advancing rapidly, but study quality varies widely. The strongest evidence supports wound healing and radiation injury management. Promising but not definitive evidence exists for TBI, stroke recovery, fibromyalgia, and long COVID at adequate doses. Anti-aging research is intriguing but preliminary. Protocol matters enormously: pressure, oxygen concentration, number of sessions, and timing all influence outcomes. Studies using 40 or more sessions at 2.0 ATA consistently show stronger effects than those using fewer sessions or lower pressures.